Altered gut microbiota and microbial biomarkers associated with chronic kidney disease

Lun, Hengzhong; Yang, Weihua; Zhao, Shuping; Jiang, Meijie; Xu, Mingjie; Liu, Fenfen; Wang, Yunshan

doi:10.1002/mbo3.678

Cited by 124 publications

(99 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Dysbiosis of gut microbiome, which results in generation of excessive nephrotoxins, may dictate the development and progression of CKD. However, current culture-independent studies of gut microbiome on CKD have been mostly focused on the advanced stage of disease [9][10][11][20][21][22]. In the present study, through analyzing the fecal samples from subjects with normal renal function and CKD patients with different disease severities, we identified intestinal bacterial biomarkers that are highly discriminatory since the early stage and mirror the disease severity of CKD.…”

Section: Discussionmentioning

confidence: 84%

“…Similarly, an elevated level of circulating pCS was found to be correlated with the increased abundance of the Ruminococcus genus in the feces of patients with early-stage CKD [12]. To date, studies of gut microbiome on CKD have been focused on either animal model or patients having advanced stages of disease [9][10][11][20][21][22] or early renal function decline [12]. Yet, the exact correlation of the gut microorganisms with gut-producing nephrotoxins and the disease progression in CKD patients having different disease stages remains largely unclear.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study

Wu¹,

Lin²,

Chang³

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

The interplay of the gut microbes with gut-producing nephrotoxins and the renal progression remains unclear in large human cohort. Significant compositional and functional differences in the intestinal microbiota (by 16S rRNA gene sequencing) were noted among 30 controls and 92 (31 mild, 30 moderate and 31 advanced) patients at different chronic kidney disease (CKD) stages (discovery cohort). A core CKD-associated microbiota consisted of 7 genera (Escherichia_Shigella, Dialister, Lachnospiraceae_ND3007_group, Pseudobutyrivibrio, Roseburia, Paraprevotella and Ruminiclostridium) and 2 species (Collinsella stercoris and Bacteroides eggerthii) were identified to be highly correlated with the stages of CKD. Paraprevotella, Pseudobutyrivibrio and Collinsella stercoris were superior in discriminating CKD from the controls than the use of urine protein/creatinine ratio, even at early-stage of disease. The performance was further confirmed in a validation cohort comprising 22 controls and 76 peritoneal dialysis patients. Bacterial genera highly correlated with indoxyl sulfate and p-cresyl sulfate levels were identified. Prediction of the functional capabilities of microbial communities showed that microbial genes related to the metabolism of aromatic amino acids (phenylalanine, tyrosine, and tryptophan) were differentially enriched among the control and different CKD stages. Collectively, our results provide solid human evidence of the impact of gut-metabolite-kidney axis on the severity of chronic kidney disease and highlight a usefulness of specific gut microorganisms as possible disease differentiate marker of this global health burden.

show abstract

Section: Discussionmentioning

confidence: 84%

Section: Introductionmentioning

confidence: 99%

Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study

Wu¹,

Lin²,

Chang³

et al. 2020

Int. J. Biol. Sci.

View full text Add to dashboard Cite

show abstract

“…[41] Holdemanella, a genus of the Firmicutes phyla, also decreased in response to HY7714 consumption; its levels are associated with constipation, an unbalanced lipid profile, and chronic kidney disease. [19,42,43] Intestinal microbiota interact with other microbes and modulate physiologic and metabolic processes. They provide specific functions and maintain gut homeostasis.…”

Section: Plos Onementioning

confidence: 99%

Regulatory effects of Lactobacillus plantarum HY7714 on skin health by improving intestinal condition

et al. 2020

View full text Add to dashboard Cite

Despite increasing research on the gut-skin axis, there is a lack of comprehensive studies on the improvement of skin health through the regulation of the intestinal condition in humans. In this study, we investigated the benefits of Lactobacillus plantarum HY7714 (HY7714) consumption on skin health through its modulatory effects on the intestine and ensuing immune responses. HY7714 consumption led to differences in bacterial abundances from phylum to genus level, including increases in Actinobacteria followed by Bifidobacterium and a decrease in Proteobacteria. Additionally, HY7714 significantly ameliorated inflammation by reducing matrix metallopeptidases (MMP-2 and MMP-9), zonulin, and calprotectin in plasma, all of which are related to skin and intestinal permeability. Furthermore, RNA-seq analysis revealed its efficacy at restoring the integrity of the gut barrier by regulating gene expression associated with the extracellular matrix and immunity. This was evident by the upregulation of IGFBP5, SERPINE1, EFEMP1, COL6A3, and SEMA3B and downregulation of MT2A, MT1E, MT1X, MT1G, and MT1F between TNFα and TNFα plus HY7714 treated Caco-2 cells. These results propose the potential mechanistic role of HY7714 on skin health by the regulation of the gut condition. OPEN ACCESS Citation: Nam B, Kim SA, Park SD, Kim HJ, Kim JS, Bae CH, et al. (2020) Regulatory effects of Lactobacillus plantarum HY7714 on skin health by improving intestinal condition. PLoS ONE 15(4): e0231268. https://doi.org/10.

show abstract

“…The microbial communities contained higher levels of Bacteroidetes and lower levels of Firmicutes in all hemodialysis patients, which is similar to CKD rat microbial communities [35] and in a human CKD microbiota study. [36] Co-occurrence analysis revealed no difference in keystone taxa Bacteroides between β-blocker users and non-users. Overall, there was an enriched genus Flavonifractor in β-blocker users in the full and PS-matched cohorts.…”

Section: Discussionmentioning

confidence: 93%

Differences in the Microbial Composition of Hemodialysis Patients Treated With and Without β-Blockers

Lin

Hung

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: β-blockers are commonly prescribed medications to treat cardiovascular disease and prevent sudden cardiac death during hemodialysis. Beyond the medication effects on the host, no study has investigated the impact of β-blocker on the gut microbiota in hemodialysis patients. Results: The β-blocker users had a higher proportion of diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, heart failure, cerebrovascular disease, and concurrent medications than non-users. After propensity score (PS) matching, there were no differences in comorbidities and concomitant medications. The α-diversity (Simpson index) increased in β-blocker users with a distinct β-diversity (Bray-Curtis Index) compared to non-users in the full cohort and PS-matched cohort. In the linear discriminative analysis effect size analysis and zero-inflated Gaussian fit model, there was a significant enrichment in the genus Flavonifractor in β-blocker users compared to non-users in the full cohort and PS-matched cohort; this was confirmed by random forest analysis. Conclusions: Hemodialysis patients using β-blocker used had a different gut microbiota composition compared to non-users, in particular, the Flavonifractor genus was significantly increased with β-blocker treatment. These findings highlight the significant impact of β-blockers on the gut microbiome in hemodialysis patients. Further research is warranted regarding the mechanisms and their clinical consequences.

show abstract

Altered gut microbiota and microbial biomarkers associated with chronic kidney disease

Cited by 124 publications

References 39 publications

Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study

Gut Microbiota as Diagnostic Tools for Mirroring Disease Progression and Circulating Nephrotoxin Levels in Chronic Kidney Disease: Discovery and Validation Study

Regulatory effects of Lactobacillus plantarum HY7714 on skin health by improving intestinal condition

Differences in the Microbial Composition of Hemodialysis Patients Treated With and Without β-Blockers

Contact Info

Product

Resources

About